PDCD1 and primary central nervous system lymphoma: (94) evaluated the safety and efficacy of combining orelabrutinib, an anti-programmed cell death 1 (PDCD1/PD-1) antibody, and formostatin to treat patients with newly diagnosed PCNSL, achieving an ORR of 88.9% in a phase I study, with a phase II study still ongoing.